SCHEMBL30015022

SCHEMBL30015022

COc1cc(N2CCC(N3CCN(C)CC3)CC2)c(C(F)(F)F)cc1Nc1ncc(Cl)c(Nc2ccc3nccnc3c2NS(C)(=O)=O)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 14/20 0.60
▸ ALK Q9UM73 7/20 0.55
▸ INSR P06213 6/20 0.55
▸ IGF1R P08069 6/20 0.55
▸ MET P08581 2/20 0.53
▸ BMPR1B O00238 1/20 0.52
▸ PLK4 O00444 1/20 0.52
▸ STK25 O00506 1/20 0.52
▸ RIOK3 O14730 1/20 0.52
▸ CHEK1 O14757 1/20 0.52
▸ CASK O14936 1/20 0.52
▸ AURKA O14965 1/20 0.52
▸ GAK O14976 1/20 0.52
▸ DCLK1 O15075 1/20 0.52
▸ MUSK O15146 1/20 0.52
▸ EPHB6 O15197 1/20 0.52
▸ PDPK1 O15530 1/20 0.52
▸ MAP3K13 O43283 1/20 0.52
▸ DAPK3 O43293 1/20 0.52
▸ MAP3K7 O43318 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27075988 1.00 EGFR (0.60) EGFRALKINSRIGF1RMET
SCHEMBL26906723 0.92 EGFR (0.64) EGFRALKINSRIGF1RMET
SCHEMBL29785219 0.91 EGFR (0.66) EGFRALKINSRIGF1RMET
SCHEMBL26906609 0.91 EGFR (0.66) EGFRALKINSRIGF1RMET
SCHEMBL27076001 0.90 EGFR (0.61) EGFRALKINSRIGF1RMET
SCHEMBL27076005 0.90 EGFR (0.67) EGFRALKINSRIGF1RMET
SCHEMBL30015109 0.89 EGFR (0.64) EGFRALKINSRIGF1R
SCHEMBL27076076 0.89 EGFR (0.64) EGFRALKINSRIGF1R
SCHEMBL29904660 0.88 EGFR (0.76) EGFRALKINSRIGF1RMET
SCHEMBL26906933 0.88 EGFR (0.76) EGFRALKINSRIGF1RMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297194-B2 N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof Bridge Biotherapeutics, Inc. (KR) 2025-05-13 — — US disclosed
US-20220332711-A1 N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF Bridge Biotherapeutics, Inc. (KR) 2022-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12297194-B2 N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof EGFR, ERBB2, ERBB4 EGFR 1/4885ALK 90/4885INSR 1593/4885
US-20220332711-A1 N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF EGFR, ERBB2, ERBB4 EGFR 1/4885ALK 90/4885INSR 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback